ClinicalTrials.gg
Not yet recruitingNCT07552987Updated Oct 22, 2026

A Study Investigating Intravenous Human Normal Immune Globulin 10% in Adults With Stiff Person Syndrome

A Phase 3 interventional study of Kedrion IVIg 10% and Human Albumin in Stiff Person Syndrome, sponsored by Kedrion S.p.A.. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Kedrion S.p.A. · Phase 3, Interventional, and Treatment

Updated Oct 22, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of QIVIGY (Intravenous Human Normal Immune Globulin 10%) compared with placebo in adult participants with stiff person syndrome (SPS).

Read the detailed description

This is a phase III, double-blind, placebo-controlled, parallel group, multicenter study to assess the efficacy and safety of QIVIGY in adult participants with stiff person syndrome.

Participants will be randomized in a 1:1 ratio, to receive either 2 g/kg of QIVIGY or equivalent volume of placebo. During the randomized phase, study treatment will be administered every 4 weeks for 24 weeks, at which point the primary efficacy endpoint assessment will be performed at an End of Randomized Treatment visit.

At this study visit, all participants will be given the option to enter an open-label study extension. Participants who choose to continue in the study will receive 2.0 g/kg QIVIGY every 4 weeks, for a duration of 24 weeks.

02

Conditions studied

  • Stiff Person Syndrome

Keywords

  • Stiff Person Syndrome
  • SPS
  • Neurological Disorders
  • Autoimmune Disease
  • Human Immunoglobulin
03

In context

Stiff-Person Syndrome

20 studies on the registry are indexed under Stiff-Person Syndrome; 8 are open to participants now.

This study's planned enrollment of 38 is above the median of 25 across 12 interventional studies indexed under Stiff-Person Syndrome.

Browse Stiff-Person Syndrome studies →

Lead sponsor

Kedrion S.p.A. is the lead sponsor of 10 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, 18-70 years of age.
  2. Patient has signed the Form (ICF).
  3. Diagnosed with SPS per the following criteria:

    a. Clinical symptoms (must have 1 of 2) i. Stiffness (axial regions, limbs, or both) ii. Episodic spasms (axial regions, limbs, or both) triggered by noises, tactile stimuli, emotional stress.

    b. Clinical signs during symptomatic phase of illness (must have 1 of 3) i. Increased muscle tone (axial or limbs) ii. Exaggerated lumbar lordosis iii. Concurrent stiffness of lumbar paraspinal and abdominal muscles. c. Serological findings (must have 1 of 2), based on participant medical history: i. High-titer GAD65-IgG in the serum (e.g. ≥ 20 nmol/L by radio-immunoprecipitation assay or 10,000 IU/mL by enzyme-linked immunoassay [ELISA]) or any positive titer in cerebrospinal fluid [CSF] ii. Glycine-R-IgG in serum and/or CSF by live cell binding assay.

  4. Patients must have paravertebral stiffness and torso/lower extremity predominance.
  5. Distribution of stiffness index score of ≥ 2, including stiffness in the legs or trunk.
  6. Patient may be Ig-naïve or Ig-pre-treated, however they should not have received Ig within 3 months prior to the time of study entry (Day 0).

    1. Includes newly diagnosed patients
    2. Includes patients who have received symptomatic treatments only
    3. Includes patients who have failed to respond to rituximab.
  7. Patients who have received rituximab in the past 18 months must have B-cell reconstitution test results available from within 3 months prior to enrolment that confirms restoration of humoral immunity.
  8. Daily symptomatic therapy has been stable for a minimum of two weeks prior to screening and is expected to remain stable throughout the duration of the study.
  9. Willing to comply with all requirements of the protocol, including travel to site for scheduled protocol assessments and treatment, and completion of a diary for the study duration.
  10. For women of (WOCBP), a negative urine pregnancy test at screening, on enrollment (Day 0), and agreement to employ effective measures during the study until the end of study (EOS) visit.
  11. Authorization to access personal health information.

Exclusion criteria

Exclusion Criteria:

  1. Patients incapable of giving .
  2. Patients with SPS-plus or variants of SPS such as paraneoplastic or progressive encephalomyelitis with rigidity and myoclonus (PERM). Patients with pure cerebellar ataxia, ocular motor apraxia.
  3. Patients who are bed-bound or wheelchair-dependent.
  4. Ongoing/active infection with virus (HBV), virus (HCV) or Type 1/2 infection. Subjects with chronic hepatitis B or hepatitis C infection currently on treatment may participate if they have undetectable viral load within 12 months of screening date.
  5. Patient with a history of to IVIg, other injectable forms of IVIg, or to glycine (used as an ).
  6. Patient with known Immunoglobulin A (IgA) deficiency and antibodies against IgA.
  7. Patients who are planning to receive the following treatments within the coming 12 months, or who have received in the stated timeframe before enrollment (Day 0)

    1. Botulinum toxin within 6 months
    2. Rituximab within 6 months
    3. -sparing (azathioprine, methotrexate, cyclophosphamide, or mycophenolate mofetil) within 1 month
    4. Plasmapheresis within 3 months.
  8. Prior chimeric antigen receptor (CAR)-T cell therapy or hematopoietic stem-cell transplantation.
  9. Received any blood, blood product, or blood derivative within 1 month of the baseline visit.
  10. Had therapy with within 3 months of the baseline visit.
  11. Use of loop diuretics within 1 week of the baseline visit.
  12. Patients at high-risk of thrombotic events such as deep vein thrombosis, cerebrovascular accident, pulmonary embolism, , or myocardial infarction.
  13. Uncontrolled hypertension (i.e., diastolic blood pressure [BP] > 100 mmHg and/or systolic BP > 160 mmHg). If a single measure exceeds this limit, a triple repeat measurement may be performed and the average of the three measurements used.
  14. Congestive heart failure as per III/IV, cardiomyopathy, cardiac arrhythmia associated with thromboembolic events (e.g., atrial fibrillation), unstable or advanced ischemic heart disease, hyperviscosity.
  15. Patients with significant protein losing enteropathy, nephrotic syndrome, or lymphangiectasia.
  16. Patients with hyperproteinemia, increased serum viscosity, and/or hyponatremia.
  17. Severe liver or kidney disease (normal reference ranges of laboratory doing the analysis):

    1. (ALT) or aspartate amino transferase (AST) >2.5x (ULN)
    2. Creatinine > 120 µmol/L
    3. Blood urea nitrogen (BUN) > 2.5x ULN.
  18. Signs of severe anemia: of less than 7 g/dL, hemodynamically unstable due to active bleeding, and/or when evidence of end-organ ischemia secondary to severe anemia is present.
  19. > 35 kg/m2 or an IVIg dose that puts the patient at risk of fluid overload.
  20. History of a malignant disease within 3 years of the baseline visit other than properly treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin.
  21. Patients having participated in an interventional, clinical study within 30 days of the baseline visit, or within 5 half-lives of the investigational medicinal product (IMP) under investigation.
  22. Any condition that the Investigator believes is likely to interfere with evaluation of the IMP or with satisfactory conduct of the trial.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    Kedrion IVIg 10%

    Participants will receive 2 g/kg IVIg 10% administered over 2-5 days at 4-week intervals for 24 weeks. Participants will have the option to enter the open label extension phase and receive IVIg 10% for 24 weeks to week 48.

    Biological: Kedrion IVIg 10%

  • Placebo comparator
    Placebo

    Participants will receive equivalent volume of placebo administered over 2-5 days at 4-week intervals for 24 weeks. Participants will have the option to enter the open label extension phase and receive IVIg 10% for 24 weeks to week 48.

    Biological: Human Albumin

Interventions

  • Intravenous human normal immunoglobulin (IVIg) 10%

    Also known as: QIVIGY, KIg10

  • BiologicalHuman Albumin

    Human albumin solution, diluted with saline 0.9% to a final concentration of 0.5% as an intravenous infusion

06

What researchers measure

Primary outcomes

  1. Timed 25-Foot Walk (T25-FW)

    Proportion of participants showing an improvement on the Timed 25-Foot Walk

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Timed 25-Foot Walk (T25-FW)

    Change in the Timed 25-Foot Walk from baseline to Week 24 and, for participants entering the study extension, to Week 48

    Time frame: Baseline up to Week 48

  2. Distribution-of-Stiffness (DSI)

    Change in the scores of the distribution-of-stiffness index (DSI) from baseline to Week 24 and, for participants entering the study extension, to Week 48

    Time frame: Baseline up to Week 48

  3. Heightened Sensitivity Scale (HSS)

    Change in heightened sensitivity scale (HSS) from baseline to Week 24 and, for participants entering the study extension, to Week 48

    Time frame: Baseline up to Week 48

  4. Modified Rankin Scale (mRS)

    Change in Modified Rankin scale (mRS) from baseline to Week 24 and, for participants entering the study extension, to Week 48

    Time frame: Baseline up to Week 48

  5. HRQoL assessments (Neuro-QOL)

    Change in score by visit

    Time frame: Baseline up to Week 48

  6. Pain Interference Score

    Change in score by visit

    Time frame: Baseline up to Week 48

  7. Change in level of walking aid dependency

    Change from baseline in level of walking aid dependency will be assessed by clinician-reported ambulatory status during scheduled clinical outcome assessments. Walking aid use (unaided, cane, or walker) will be recorded at baseline and at each study visit. Improvement is defined as a reduction in level of assistance (e.g., from walker to cane or unaided, or from cane to unaided).

    Time frame: Baseline up to Week 48

  8. Assess Safety

    Assess treatment-emergent AEs and SAEs

    Time frame: Day 0 to Week 48

  9. Duration of Response

    Participants on QIVIGY in the randomized phase who responded to treatment will be assessed for continued change (duration of response) through 12 months, based on the T25-FW Test

    Time frame: Week 24 to Week 48

  10. Time to response

    Participants on placebo in the randomized phase and did not achieve a response will be assessed for time to response to QIVIGY based on the T25-FW Test

    Time frame: Week 24 to Week 48

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Publishing of data and IPD that underlie results in the publication will be determined at study completion to comply with ICMJE minimum requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Jan 2028, 14 months later.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2026
First posted
Apr 27, 2026
StartEst.
Nov 2026was Sep 2026
Primary completionEst.
Jan 2028
CompletionEst.
Jul 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Nov 2026
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Start date Sep 2026→Nov 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07552987
Lead sponsor
Kedrion S.p.A.
Responsible party
Sponsor
First posted
Apr 27, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Cecilia Conz
Contact
c.conz@kedrion.com
+39 331 6267651
Nicola Rovai
Contact
n.rovai@kedrion.com
+39 335 6524750
Miranda Norton, PhD
study chair · Kedrion S.p.A.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion